BioMarin (BMRN) Affirms Briefing Docs Posted for Vimizim Ahead of FDA Panel
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the U.S. Food and Drug Administration (FDA) posted briefing materials for the November ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
